The global prevalence of cardiovascular diseases (CVDs) has increased rapidly, accounting for nearly 18 million deaths per year and is expected to rise to over 23 million by 2030 (World Health Organization 2021). A compromised heart function results from myocardial damage caused by hypertension, atherosclerosis, heart attack, arrhythmia, or heart failure. Though heart transplantation is the gold standard treatment, the shortage of donor hearts and the risk of rejection are major limitations in treating CVD patients. Current treatment options can only manage end-stage heart disease using assisted devices (Capriotti and Micari 2019), hence there is a compelling need for effective treatment options. In the past decades, stem cells have been considered a safe and effective tool to improve the cardiac function of damaged hearts. However, clinical trials such as Allogenic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR) (Makkar et al., 2020), Cardiosphere-derived autologous stem cells to reverse ventricular dysfunction (CADUCEUS) (Makkar et al., 2012), demonstrated poor retention, low survival, and risk of arrhythmias in stem cell transplanted patients (Banerjee et al., 2018; Menasché 2018).

Exosomes, which are naturally formed nanocarriers (30–150 nm) of endocytic origin, play a crucial role in maintaining vascular integrity and cardiovascular health (Sahoo et al., 2021). They carry various biomolecules, e.g., proteins, lipids, RNA, DNA, long non-coding RNA (lncRNA), siRNA, etc., and transfer them to the target cells (Kowal et al., 2014). Owing to their role in maintaining cardiovascular health, exosomes, especially those secreted by stem cells, are considered attractive candidates for regenerative therapies (Sahoo and Losordo 2014). Unlike stem cells, exosomes derived from them are more stable during cryopreservation, are non-immunogenic, non-teratogenic and possess better retention potential post injection besides their ability to cross biological barriers (Marbán 2018). Hence, stem cell exosomes offer new hope in cell-free paracrine therapies for myocardial repair.

The therapeutic utility of exosomes against CVDs, especially those secreted by cardiac cells post-pathological insult, is being increasingly explored (Kishore and Khan, 2017; Saha et al., 2019). Understanding the characteristic properties of various cardiac cell-derived exosomes and their effects on cardiac function is one of the key areas of interest in CVDs (Rezaie et al., 2019). Stem cells of the human heart tend to secrete exosomes in response to injury, a part of which is also released into the circulation (Barile and Vassalli 2017), suggesting their crucial role as biomarkers for early diagnosis of CVDs. In this context, cardiac specific micro RNAs (miRNAs) present in exosomes have garnered huge attention (Zhou et al., 2018; Henning 2021). miRNAs are group of small non-coding RNAs of about 17–25 nucleotides, which act as post-transcriptional regulators of physiological processes (Wang J et al., 2016). Recent years have witnessed the implementation of various engineering strategies to develop exosome-based novel off-the-self therapeutics (Luan et al., 2017; Murphy et al., 2019). In the current review, we provide comprehensive information on stem cell-derived exosomes, their unique features, and highlight the mechanisms of their cardioprotective functions. We further discuss potential applications of exosomes as diagnostic and therapeutic tools in the treatment of CVDs, focusing on current advancements made in the field, including prospective future directions.

Owing to their self-renewability and differentiation abilities, stem cells are promising candidates for regenerative therapies. However, the current focus on stem cells is being surpassed by exosomes derived from them, which are superior, safer, and scalable cell-free alternatives (Ong and Wu 2015). Stem cell-derived exosomes’ biogenesis and extraction methods have been reviewed in detail elsewhere (Li et al., 2017; Balbi and Vassalli 2020). In this section, we discuss the pleiotropic action of various stem cell-derived exosomes in regulating myocardial functions as illustrated in Figure 1A.

Mesenchymal stem cells (MSC) are multipotent in nature and possess great regenerative potential (Charles et al., 2020). They are isolated from various adult tissues, primarily bone marrow (BM), adipose tissue, and endometrium (Pittenger et al., 2019). Though the safety profile of MSC therapy is well known, its efficacy is not yet clear (Karantalis and Hare, 2015; Hare et al., 2017). Several preclinical and clinical studies confirmed improvement in cardiac functions post-MSC therapy (Razeghian-Jahromi et al., 2021), but clinical outcomes were variable (Perin et al., 2014). For example, a comparative study of three clinical trials showed variable effects of MSC therapy in DCM and ICM patients. While in DCM patients, MSC administration improved cardiac functional parameters, in ICM patients it induced cardiac remodeling (Tompkins et al., 2018). Over the past few years, MSC-derived exosomes (MSC-Exo) have gained increasing impetus. A comparative miRNA analysis of MSC and MSC-Exo revealed similarities in their miR expression profiles and superior cardioprotection offered by MSC-Exo treatment in rat MI model. Notably the expression of miR-21 and miR-15, which are associated with hypertrophy and ischemic injury respectively were lower in MSC-Exo compared to MSC. The authors further demonstrated that MSC-Exo treatment in vivo markedly reduced inflammation, inhibited fibrosis, and improved cardiac function in MI rats (Shao et al., 2017). Consistently, MSC-Exo attenuated cardiac inflammation after ischemia/ reperfusion (I/R) injury in mice. Following exosome treatment for 3 weeks, IL6 levels were significantly reduced and IL10 was elevated in the heart tissue. In addition, miR182-mediated macrophage polarization was also observed by MSC-Exo via miR182 (Zhao et al., 2019). The molecular cargo of MSC-Exo is modified in response to cardiac injury or in stressful conditions. For example, MSC-Exo enhanced H9C2 cell viability in vitro and reduced ROS production in an H2O2 stimulated myocardial ischemia reperfusion injury (MIR) injury rat model (Liu et al., 2017; Xiao et al., 2018). Interestingly, MSC-Exo regulated autophagy by reducing the levels of Bnip3 and LC3-II via miR-125b-5p in a murine MI model (Xiao et al., 2018). Exosomal cargo modulates autophagy in target cells to maintain cellular homeostasis in stressful conditions using different signaling pathways including Akt/mTOR, EGFR, and TLR signaling, etc. (Hassanpour et al., 2020).

A mechanistic insight into the adipose-derived MSC-Exo revealed Wnt/β-catenin mediated regulation of survival and apoptosis in cardiomyocyte (CM) and rat I/R-injury model (Cui et al., 2017). Recently the efficacy of MSC-Exo derived from ESC was reported in a preclinical study, where MSC-Exo when administered systemically in a porcine MI model via intravenous bolus injection for 7 days resulted in a significant reduction of the infarct size by 30%–40% and cardiac function was improved in comparison to control (Charles et al., 2020). Thus, MSC-Exo possesses immense potential to restore cardiac function.

Human embryonic stem cells (ESC), characterized by their unlimited self-renewal capacity and differentiability to any somatic cell type (Müller et al., 2018), are brilliant candidates for regenerative therapies. However, despite encouraging results, ethical challenges associated with the destruction of human embryos, immune rejection and safety issues concerning malignant transformations hamper their clinical use in regenerative therapies (Volarevic et al., 2018). Consequently, ESC-derived exosomes (ESC-Exo), which are the acellular derivatives of ESC, are being investigated (Kishore and Khan 2016). Molecular miRNA analysis revealed an enrichment of the miR-290-295 cluster, particularly miR-294 in murine ESC-Exo. Intramyocardial delivery of such exosomes reduced fibrosis, induced neovascularization, and augmented cardiac functions in mice following MI (Khan et al., 2015). Interestingly, human-ESC-derived cardiovascular progenitor cells extracellular vesicles including exosomes (ESC-Pg-Exo) reportedly improved ejection fraction, capillary density, and reduced infarct size after 6 weeks of treatment post-MI in a mouse model similar to their cellular counterpart (Kervadec et al., 2016). Similarly, human-derived ESC-Pg-Exo under hypoxia conditions promoted myocardial infarct healing by improving CM survival and angiogenesis, primarily regulated by lncRNA MALAT1 via targeting miR-497 (Wu et al., 2020). Thus, ESC-Exo can act as a potent cell-free alternative to ESC, and further studies are desired in this context.

The breakthrough discovery of Yamanaka factors’ having ability to reprogram somatic cells marks the descent of the era of induced pluripotent stem cells (iPSC). These cells are generated from reprogrammed adult somatic cells and have the ability to differentiate into any cardiac lineages (Lalit et al., 2014). In addition, they can be obtained from patients who allow autologous therapeutic options without any ethical concerns like ESC. However, tumorigenic potential, risk of arrhythmias and low retention rate have been the potential limitations in this area (Wang et al., 2015; Müller et al., 2018). Thus, iPSC-derived exosomes (iPSC-Exo) are being explored for precision medicine against CVDs (Yang 2018). From molecular analysis, iPSC-Exo was identified to express pluripotency-related markers like Oct3/4A, Nanog, and Sox2, similar to iPSC and miRNAs involved in angiogenesis, cell cycle regulation, and hypoxia adaption (Zhou et al., 2016; Adamiak et al., 2018). Previously, the miRNA and lncRNA profiles of human derived ESC-CM-Exo and iPSC-CM-Exo harvested under hypoxic and normoxic conditions were found to be similar including the expression of cardioprotective miRs like mi-R1, miR-21, and miR-30 (Lee et al., 2017). A q-PCR analysis showed the abundance of miR-21 and miR-210 in iPSC-Exo, known for their cardioprotective roles by targeting programmed cell death protein 4 and Ephrin-A3, inhibiting apoptosis and promoting angiogenesis (Nazari-Shafti et al., 2020).

The safety and efficacy of iPSC-Exo have been reported in preclinical studies (Jung et al., 2017). Earlier, cardiac fibroblast (CF) derived iPSC-Exo protected H9C2 CM from H2O2-induced oxidative stress by suppressing Caspase 3/7 activation. Intramyocardial injection of iPSC-Exo also exerted an anti-apoptotic effect in the MIR injury mouse model (Wang et al., 2015). Another comparative analysis of exosomes of iPSC derived from CF and dermal fibroblast of Heart Failure (HF) patients revealed lower expression of miR22 in iPSC-Exo, reflecting a loss of hypertrophy memory and attenuating cardiac remodeling. Further iPSC-Exo treatment significantly improved the differentiation of embryoid bodies to CM in vitro (Kurtzwald-Josefson et al., 2020). Similarly, iPSC-derived extracellular vesicles including exosomes were found cytoprotective by inducing angiogenic, migratory, and anti-apoptotic properties in cardiac endothelial cells in vitro. The authors further reported an improved left ventricle (LV) function of the infarcted heart when iPSC-Exo was injected intramyocardially in MI mice. While iPSC injections led to teratoma formation, iPSC-Exo was found to be safer (Adamiak et al., 2018).

In addition, exosomes from iPSC-derived cells are considered a promising source for autologous delivery of cardiac specific bioactive contents (Jung et al., 2017). Notably, iPSC-derived cardiomyocytes (iCM) exosomes (iCM-Exo) were found to mimic iCM as they contain CM specific cargo (Santoso et al., 2020). In this study, iCM-Exo enhanced the CM’s survival in hypoxic conditions in vitro and improved cardiac function in a murine MI model. Also, iCM-Exo upregulated autophagy and autophagic flux during hypoxia-ischemia stress. In another study, human iPSC-derived cardiac cell (iPSC-CC) exosomes protected iCM by reducing apoptosis, maintaining calcium homeostasis and increasing energy metabolism. In vivo, they improved myocardial function, wall stress, and cardiac hypertrophy of the porcine infarcted heart without increasing arrhythmogenic frequency (Gao et al., 2020). However, a recent comparison of efficiacy of exosome isolated from iPSC-derived cardiovascular progenitor cells (iPSC-Pg-Exo) and iCM-Exo revealed superiority of iPSC-Pg-Exo in improving the survival, proliferation of CMs in vitro and also promoting angiogenesis of HUVECs in a dose-dependent manner. Further iPSC-Pg-Exo improved cardiac function by significantly enhancing Left ventricle ejection fraction (LVEF) and reducing left ventricular volumes in comparison to iCM, 7 weeks after exosomes treatment to chronic HF mouse model (El Harane et al., 2018). Thus, exosomes from iPSC and iPSC-derived cells hold great potential for the development of patient-specific regenerative therapies against CVDs.

Cardiac stem cells residing in the heart are unique owing to their origin, cardio-specific cargo, and inherent regenerative capacity (Messina et al., 2004). These multipotent cells resident in the human heart are clonogenic, have a defined cardiac fate, and can differentiate into cardiac-committed cells, which are affected by their ambience in pathological settings (Khaksar et al., 2018). The regenerative potential of human cardiac progenitor cells (CPC) and cardiosphere-derived cells (CDC), which are harvested from human tissue specimens, is well known from earlier clinical trials (Makkar et al., 2012). However, poor survival and poor functional integration of transplanted cells restricted their clinical translation (Gnecchi et al., 2008). Hence, the therapeutic potency of exosomal-derivatives of cardiac cells is gaining major attention for cardiac repair and regeneration (Sahoo and Losordo 2014).

CPC-derived exosomes (CPC-Exo) recapitulate the therapeutic benefits of CPC (Müller et al., 2005). The cardioprotective ability of patient-derived CPC-Exo was found superior to BM-Exo by preventing CM apoptosis in vitro and improving ventricular function in I/R rats, which was mediated by PAPP-A enriched in CPC-Exo (Barile et al., 2018). In another study, CPC-Exo released under hypoxic conditions showed enhanced proangiogenic and antifibrotic activity in vitro and improved heart function in an I/R injury model (Gray et al., 2015). Interestingly, CPC-Exo treatment nullified the Doxorubicin/Trastuzumab (cancer drug)-driven cardiotoxicity by attenuating fibrosis and iNOS expression (Milano et al., 2020). Similarly, mouse heart derived CPC-Exo protected CM from oxidative stress in I/R injury mouse exhibiting an anti-apoptotic effect mediated by miR-451 (Chen et al., 2013). During viral myocarditis H9C2 infected with coxsackievirus B3, rat-derived CPC-Exo exhibited anti-apoptosis by inducing Bcl-2 activity and inhibiting caspase-3 and 9 cleavages (Li et al., 2019). Thus, CPC-Exo is packed with potent regulators for restoration of the damaged heart. Likewise, CDC exosome (CDC-Exo) mimicked the cardio-regenerative ability of CDC (Li et al., 2012). A number of preclinical studies pointed towards significant improvement in heart function following CDC-Exo treatment. For example, human CDC-Exo induced regeneration of the infarcted heart by promoting CM survival and angiogenesis. Following CDC-Exo treatment, cardiac function improved in MI mice, primarily mediated by miR-146a (Ibrahim et al., 2014). Recently, a randomized preclinical study in a porcine MI model revealed improved cardiac function, reduced scar-size, and an antifibrotic effect of CDC-Exo (Gallet et al., 2017). Further, the authors elucidated that the efficacy of CDC-Exo was notable when delivered intramyocardially, while intracoronary delivery was ineffective. Consistently, CDC treatment resulted in increased neovascularization, myocyte proliferation, and reduced fibrosis that was abolished by blunting the exosomal release, suggesting possible CDC-Exo mediated myocardial improvement (Hirai et al., 2020). Additionally, the immunomodulatory role of CDC-Exo was reported to be superior to MSC-Exo in a comparative study, where CDC-Exo polarized M1 macrophages to an M2-like phenotype in a mouse MI model, reducing inflammation (Walravens et al., 2021). Following CDC-Exo treatment, cardiac function was improved 4 weeks post-MI by reducing scar size and increasing infarct wall thickness. Thus, CDC-Exo is a promising therapeutic candidate for treating CVDs.

CMs, the chief cell type of the heart, play a crucial role in the cardiac conduction system. CM-derived exosomes (CM-Exo) are enriched in heat shock proteins (Hsp20, Hsp60, Hsp70) attributed to CM growth and survival under stress (Gupta and Knowlton, 2007). For example, elevation of Hsp20 in CM promoted exosome secretion, CM^Hsp-Exo imparted cardioprotection by inducing angiogenesis in hyperglycemic stress conditions in vitro and attenuated diabetes-induced cardiac dysfunction and remodeling (Wang L. et al., 2018). Similarly, hypoxia-induced CM-Exo promoted apoptosis and inhibited proliferation, migration, and invasion of CF in vitro and in vivo via lncRNA AK139128 (Wang and Zhang 2020). Interestingly, glucose-deprived conditions induced secretion of CM-Exo loaded with glucose transporters and glycolytic enzymes, which mediated crosstalk between EC, suggesting metabolic regulation (Garcia et al., 2016). Additionally, ischemia-induced CM-Exo contains high amounts of MMP9 and MMP2, which are responsible for ECM degradation and tissue remodeling (Ribeiro-Rodrigues et al., 2017). Apart from the beneficial effects of CM-Exo, detrimental effects are also reported. For example, CM-Exo mediated adverse remodeling of the heart by inducing cardiac fibrosis via miR-208a. CM-Exo were enriched in miR-208a in hypoxic conditions, which was transferred to CF, promoting their proliferation and differentiation into myofibroblasts in vitro. Inhibition of miR-208a reduced cardiac fibrosis and improved cardiac function in MI rats (Yang et al., 2018). Thus, CM-Exo plays a major role in cardiac remodeling.

Taken together, all these observations suggest that stem cell exosomes offer immense potential to heal the wounded heart, as illustrated in Figure 1A. A summary of the cardioprotective mechanisms exhibited by stem cell exosomes from various in vitro and in vivo studies is listed in Table 1.

After decades of research into stem cell therapy, research into exosomes has started to gain attention as a tool to counteract CVDs (Sahoo and Losordo, 2014; Wang et al., 2020). These natural nanocarriers are exploited as sources of biomarkers present in biofluids and as therapeutic drug delivery vehicles (Figures 1B–D).

Biomarkers are molecules found in various biofluids that reflect the pathophysiological state of an individual, indicate the risk of future adverse events and predict response to treatment (Xue et al., 2020; Rezaie et al., 2021). In the past, several biomarkers have been identified for CVDs, of which cardiac Troponin T and I are considered the most reliable (Babuin and Jaffe 2005). However, in a large cohort study, their concentrations were found to vary between genders and in different age groups (Welsh et al., 2018). Hence, stable biomarkers are sought for CVD diagnosis. Several molecular studies reported alteration of exosomal protein cargos in various CVDs. For example, a proteome study of microvesicles of MI patients revealed modulated expression of 252 proteins, of which six proteins were key regulators of MI progression (Cheow et al., 2016). Compared to healthy subjects, blood exosomes of atherosclerosis patients were differentially enriched in proteasomal proteins such as PSMA6, PSMA7, and Annexin 2A (Jiang et al., 2016). Similarly, exosomal miRNAs (Exo-miR) are being extensively investigated for their diagnostic potential, especially cardiac miRs, which are known to be upregulated during CVDs (Colpaert and Calore 2019). The half-life of these miRs may vary in the patient’s serum/plasma, affecting their detection. However, crucial cardiac miRs released post-injury are reportedly carried safely by exosomes. Compared to circulating miRs released from blood cells and to some extent by dying cells (Zhou et al., 2018), the Exo-miRs are more stable and resistant to harsh environments because of their surrounding lipid envelope, hence are extremely promising as next-generation biomarkers.

Several preclinical studies indicate that Exo-miRs have superior diagnostic and prognostic value over unenveloped miRs (Gallo et al., 2012). In a retrospective multicenter study on HF patients, p53-responsive miRNAs, miR-192, miR-194, and miR-34a were found to be upregulated in exosomal fractions isolated from HF patients compared to controls. The authors advice further investigations with increased sample size and in other cohorts to confirm the present findings and future clinical applications of the Exo-miRs as predictive indicators of HF (Matsumoto et al., 2013). The serum exosomes of patients with ST-Elevation Myocardial Infarction (STEMI) showed increased levels of lncRNA, NEAT1 and miR-204 compared to controls. However, the specificity and sensitivity being low, serum exosomal NEAT1, miR-204, and MMP9 are considered useful only for auxiliary diagnosis of acute STEMI (Chen et al., 2020). In AMI mice, increased circulating levels of myocardial miR-1, 208b, and 499 were predominantly present in circulating exosomes and miR-133 in the non-exosomal component. Notably, these results were reproduced in humans as acute STEMI significantly increased circulating exosomal myo-miRs. However its clinical translation is still pending (Cheng et al., 2019). Recently, various serum Exo-miRs; miR-103a, 107, 320d, 486 and let7b were highly upregulated and acted as fair predictors of Atrial fibrillation progression (Mun et al., 2019). Prediction of HF, which is the terminal point of all heart ailments, still remains elusive, especially in the presence of other co-morbidities, e.g., obesity, diabetes, etc., which also affect the levels of Exo-miR (Patil et al., 2019). Plasma Exo-miR425 and Exo-miR744 are negative regulators of fibrosis and predictors of fibrosis and HF (Wang L. et al., 2018). Similarly, serum exosomal miR-92b is a potent marker of HF resulting from dilated cardiomyopathy, which still remains tough to diagnose due to the lack of suitable molecular diagnostics (Wu et al., 2018). To summarize, the elevated concentrations of various miRNAs in exosomal fractions have been increasingly observed during CVDs as shown in Figure 1B. However majority of investigators have suggested the need for follow-up studies in larger cohorts to confirm the clinical utility of the potential biomarkers studied by various research groups. Ongoing clinical trials include NCT03034265, where exosomal biomarkers are investigated for monitoring hypertension (ClinicalTrails.gov 2017); NCT04127591, where miRNA profiles of plasma exosomes are analyzed in MI patients (ClinicalTrails.gov 2019); the outcome of such studies is much awaited. Thus, despite accelerating research in the area, more detailed clinical investigations are needed along with multi-center studies pertaining to larger patient populations especially focused on exosomes in biofluids for faster bench to bedside conversion.

Targeted delivery of therapeutic exosomes is crucial for the effective treatment of CVDs. Earlier, synthetic carriers such as liposomes or polymeric nanoparticles have been widely used for drug delivery (Matoba et al., 2017). Recently, exosomes have been used to carry therapeutic molecules to the target tissue and have been found safe in preclinical studies (Gallet et al., 2017; Hirai et al., 2020). Although exosomes are endowed with several unique properties suitable for an ideal delivery system (Yang et al., 2015; Bellin et al., 2019), they have potential limitations as well. In this context, suboptimal biodistribution and low retention at the site of injury, along with a shorter half-life, are critical bottlenecks. Additionally, due to their uptake by the resident macrophages inside the spleen, lungs, and liver, they lead to their accumulation followed by clearance, thus forbidding their reach to the target site (Saunderson et al., 2014; Qiu et al., 2019).

To overcome these issues, researchers have implemented various nanotechnology and genetic engineering-based approaches to enhance the biodistribution, organ-specific targeting, and efficacy of exosomes. The biodistribution of endogenous exosomes was manipulated using magnetic nanoparticles that led to the accumulation of exosomes expressing CD63 in the injured CM (Liu et al., 2020). A recent study demonstrated that delivery of exosomes loaded with Clatherin-specific siRNA initially blocked their uptake by macrophages. Subsequent injection of exosomes loaded with therapeutic molecules bypassed the liver or spleen and reached the myocardium, as shown in the doxorubicin-induced cardiotoxicity model (Wan et al., 2020). To ensure cardiac homing, transmembrane proteins of exosomes were restructured by conjugating them with “cardiac homing peptide (CHP)” i.e., CSTSMLKAC. Upon their intravenous administration, exosomal retention in the infarcted myocardium was significantly improved (Vandergriff et al., 2018). However, the mechanism of CHP interaction with myocardium is still unknown. Likewise, MSC-Exo fused with “ischemic myocardium targeted peptide” enhanced the specificity and efficiency of their targeting (Wang X. et al., 2016). Intramyocardial administration of exosomes is encouraged instead of systemic administration, as the later led to an accumulation of exosomes in the liver (Bala et al., 2015). Interestingly, CPCs were genetically modified to overexpress CXCR4 for homing of exosomes to the injured myocardium. Intravenous administration of CPC^CXCR4- Exo resulted in efficient CM survival in vitro, uptake by CM ex vivo and improved LV function in I/R rats (Ciullo et al., 2019). Since pathological remodeling of heart is predominantly contributed by loss of CM, therefore, engineering of the endogenous cardiac exosomes can enhance their retention in the heart. Recently, CDC-Exo was engineered to express Lamp2b and fused with cardiomyocyte specific binding peptide (CMP). As a result, the uptake of CMP tagged exosomes into CM was enhanced, following decreased apoptosis and increased retention in the heart in comparison to the non-targeted ones (Mentkowski and Lang 2019). Thus, engineering exosomes for organ-specific or cell-specific delivery offers new hope for the development of targeted therapeutics.

Several strategies are used to modify the therapeutic properties of exosomes. Stem cell exosomes can be loaded via electroporation, sonication, co-incubation or stimulation with cardioprotective agents, resulting in reparative exosomes that are taken up during biogenesis (Luan et al., 2017). Recently, Huang et al. have shown that atorvastatin pre-treated MSC-Exo showed superior cardioprotective benefits in vitro than the untreated ones and improved systolic function of the infarcted heart in AMI rats (Huang P. et al., 2020). The authors have identified lncRNA H19 as the key mediator of pro-angiogenesis resulting from atorvastatin treatment.

Functional regeneration of the myocardium largely relies on the local concentration of exosomes. Low retention due to rapid clearance and short circulation half-life (Ibrahim and Marbán 2016) diminishes their systemic biodistribution. Although a comparative study on exosome delivery showed greater myocardial retention via intramyocardial injection than intracoronary (Gallet et al., 2017), continuous administration of exosomes by such invasive procedures is clinically challenging. Tissue engineering approaches are being exploited to enhance the retention time by facilitating the controlled release of exosomes from the target region (Vader et al., 2016). In this regard, biomaterials such as hydrogels have emerged as a preferred choice as they are biodegradable, biocompatible, and able to slowly release the encapsulated exosomes at the injected site (Han et al., 2020). Endothelial progenitor cell exosomes encapsulated in hydrogel showed sustained release of exosomes for an extended period when injected into the ischemic myocardium (Chen et al., 2018). Additionally, cardiac patches have been used to deliver stem cells or therapeutics for cardiac retention (Seif-Naraghi et al., 2013). Interestingly, an acellular artificial cardiac patch was developed using a decellularized porcine extracellular matrix scaffold and synthetic cardiac stromal cells that promoted cardiac recovery in a rat AMI model (Huang K. et al., 2020). Furthermore, direct injection of exosome encapsulated hydrogel into the pericardial cavity forms a cardiac patch in situ, proving to be an effective and minimally invasive way for therapeutic delivery (Zhu et al., 2021). Thus, engineering exosomes in hydrogel offers a minimally invasive method for myocardial recovery (Figure 1C).

Though natural exosomes serve as an excellent system for delivery of therapeutic molecules, their insufficient number, heterogeneity, and scalability are major setbacks for clinical translation. Therefore, nanomedicine approaches are implemented to synthesize exosome mimetics tailored with the advantages of natural exosomes and synthetic components (Armstrong and Stevens, 2018; Villarreal-Leal et al., 2021). Engineered exosomes can be modified to contain a “Do not eat me” signal to increase the circulation time and avoid clearance by the immune system (Sun et al., 2020). Biodistribution of biomimetic nanoparticles was improved by coating nanoparticles with the RBC membrane, making them non-immunogenic, increasing circulation time and avoiding clearance by liver or immune cells (Liang et al., 2018). For controlled release of cargo at the target site, enzyme responsive strategies were developed to deliver therapeutic molecules to the infarcted heart using matrix metalloproteinase (MMP) enzyme in a minimally invasive way. When injected intravenously, biomimetic nanoparticles reached the infarcted area and released the therapeutic content based on environmental levels of MMP (Nguyen et al., 2015). Platelet inspired nano cells (PINC) where a platelet membrane with modified prostaglandin E2 exerted specific homing ability and incorporated the cardiac stromal cell secreted factors that specifically targeted the heart with ischemic injury (Su et al., 2019). Taken together, modifying the innate exosome properties via genetic engineering or nanotechnology may overcome their limitations and offer new hope for effective CVD treatment (Figure 1D).

Stem cell exosomes seem promising as candidates for mending the broken heart. Over a decade of ongoing research on stem cells has exhibited improvements in the damaged heart, yet stem cell-derived acellular nanocarriers stand superior in terms of stability, bioavailability, and storage. Exosomes exert pleiotropic effects on the damaged myocardium by improving neoangiogenesis, cardiac conductance, autophagy, and suppressing inflammation and apoptosis, leading to functional improvements. While such studies were performed in smaller animal groups, more studies are desired in larger groups to delineate their true efficacy. The major challenge facing exosome research is the large-scale production of clinical grade exosomes, which is hindered by a lack of standard isolation techniques, heterogeneity, and low exosome yield. Interestingly, a recent attempt to develop large-scale production of GMP-grade exosomes from CPC-Exo has been appealing (Andriolo et al., 2018). More such studies are desired in this area, for an optimized and cost-effective protocol for sufficient production of exosomes, which may possibly meet the clinical needs. Exosomes in circulation holds great diagnostic potential as early biomarkers because of their increasingly proven abundance and stability in pathological milieu. As exosomes tend to interact with cells in different ways, either via receptor mediated interaction or internalization or via fusion with the cytoplasmic membrane, the therapeutic efficacy of drug-loaded exosomes is largely dependent on the mode of interaction. Consequently, understanding the molecular mechanisms will eventually improve selective drug targeting, and prevent off-target side effects. Besides tailoring exosomes with desirable properties, using novel engineering approaches and biomimetics platforms may offer potential solutions to circumvent the challenges associated with natural exosomes like unwanted side effects, biodistribution and clearance. As the exosome-mimetics field is advancing rapidly with innovative strategies, exosome-based therapeutics will not remain far from meeting clinical needs. However, more research is needed in this area to unleash the prospects of exosomes in CVD treatment.